Pantoprazole Mercapharm

Pantoprazole, the active ingredient in Pantoprazole Mercapharm, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, erosive oesophagitis and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Pantoprazole Mercapharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Mercapharm is a proton‑pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for: - Gastro‑oesophageal reflux disease (GERD): relief of heartburn and healing of erosive esophagitis. - Erosive oesophagitis: promotes healing of acid‑induced esophageal lesions. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumors.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: renal inflammation. - Severe hypersensitivity: rash, angio‑edema, anaphylaxis. - Osteoporotic fractures: increased risk with long‑term use. - Low magnesium (hypomagnesemia): muscle cramps, arrhythmia. - Liver enzyme elevation: potential hepatotoxicity.

When prescribing Pantoprazole Mercapharm, consider the following safety measures: - Renal impairment: dose adjustment may be required. - Hepatic impairment: use with caution in severe liver disease. - Long‑term therapy: monitor bone health and magnesium levels. - Pregnancy: only if clearly needed; discuss risks with a healthcare professional. - Breastfeeding: assess benefit‑risk ratio before use. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole can affect the plasma concentrations of several co‑administered medicines. Awareness of these interactions helps optimise therapy.

Major Interactions (Avoid): - Antifungal agents (e.g., ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (e.g., atazanavir, nelfinavir): decreased plasma levels. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Methotrexate: reduced renal clearance, risk of toxicity. - Digoxin: slight increase in serum concentration.